Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection

Experimental Parasitology
Sanjiva BimalPradeep Das

Abstract

We have evaluated the effect of combining CD2 with conventional antimonial (sb) therapy in protection in BALB/c mice infected with either drug sensitive or resistant strain of Leishmania donovani with 3×10(7) parasites via-intra-cardiac route. Mice were treated with anti CD2 adjunct SAG sub-cutaneously twice a week for 4 weeks. Assessment for measurement of weight, spleen size, anti-Leishmania antibody titer, T cell and anti-leishmanial macrophage function was carried out day 0, 10, 22 and 34 post treatments. The combination therapy was shown boosting significant proportion of T cells to express CD25 compared to SAG monotherapy. Although, the level of IFN-γ was not statistically different between combination vs monotherapy (p=0.298) but CD2 treatment even alone significantly influenced IFN-γ production than either SAG treatment (p=0.045) or with CD2 adjunct SAG treatment (p=0.005) in Ld-S strain as well as in Ld-R strain. The influence of CD2 adjunct treatment was also documented in anti-leishmanial functions in macrophages. As shown, the super-oxide generation began enhancing very early on day 10 after SAG treatment with CD2 during which SAG action was at minimum. Interestingly, the super-oxide generation ability remained inta...Continue Reading

References

Jan 1, 1986·Transactions of the Royal Society of Tropical Medicine and Hygiene·A E HarithJ J Laarman
Dec 1, 1986·The Journal of Infectious Diseases·R BadaroW D Johnson
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·R MukhopadhyayB P Rosen
Oct 23, 1997·The Journal of Infectious Diseases·S SundarH W Murray
Oct 7, 2000·The Journal of Infectious Diseases·H W MurrayJ P Sypek
Mar 31, 2001·Transactions of the Royal Society of Tropical Medicine and Hygiene·Z BabalooM B Eslami
Apr 5, 2001·Trends in Immunology·B PulendranC Maliszewski
Apr 18, 2001·The Journal of Biological Chemistry·D LégaréM Ouellette
May 29, 2001·The Journal of Biological Chemistry·H Yang, E L Reinherz
Jul 23, 2003·Current Drug Targets. Immune, Endocrine and Metabolic Disorders·M A PanaroV Mitolo
Nov 10, 2006·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·M OuelletteB Papadopoulou
Oct 2, 2007·Experimental Parasitology·Sanjiva BimalPradeep Das
Dec 7, 2007·Antimicrobial Agents and Chemotherapy·Jayati Mookerjee BasuSyamal Roy
Nov 1, 1986·Immunology Today·W Dröge

❮ Previous
Next ❯

Citations

Jul 23, 2013·PLoS Neglected Tropical Diseases·Yahya SohrabiMarie Lipoldová
Dec 3, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ling ZhangXuemei Hu
Jun 17, 2015·BioMed Research International·Juliana Perrone Bezerra de MenezesPatrícia Sampaio Tavares Veras
Aug 27, 2013·Drug Discovery Today·Keerti Jain, Narendra K Jain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.